Induction of potent anti-tumor responses while eliminating systemic side effects via liposome-anchored combinatorial immunotherapy.

[1]  S. Cornwall,et al.  CD40‐activated B cells contribute to mesothelioma tumor regression , 2011, Immunology and cell biology.

[2]  S. Antonia,et al.  Immune modulation with weekly dosing of an agonist CD40 antibody in a phase I study of patients with advanced solid tumors , 2010, Cancer biology & therapy.

[3]  R. Tibshirani,et al.  In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  N. Munshi,et al.  A phase I multidose study of dacetuzumab (SGN-40; humanized anti-CD40 monoclonal antibody) in patients with multiple myeloma , 2010, Haematologica.

[5]  Yanrong Wu,et al.  DNA-based micelles: synthesis, micellar properties and size-dependent cell permeability. , 2010, Chemistry.

[6]  J. Allison,et al.  PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors , 2010, Proceedings of the National Academy of Sciences.

[7]  J. Lustgarten,et al.  Targeting the tumor microenvironment with anti-neu/anti-CD40 conjugated nanoparticles for the induction of antitumor immune responses. , 2010, Vaccine.

[8]  D. Irvine,et al.  Engulfing tumors with synthetic extracellular matrices for cancer immunotherapy. , 2009, Biomaterials.

[9]  Daniel G. Anderson,et al.  Nanoparticle-Delivered Multimeric Soluble CD40L DNA Combined with Toll-Like Receptor Agonists as a Treatment for Melanoma , 2009, PloS one.

[10]  C. Ahonen,et al.  In situ stimulation of CD40 and Toll-like receptor 3 transforms ovarian cancer-infiltrating dendritic cells from immunosuppressive to immunostimulatory cells. , 2009, Cancer research.

[11]  Hua Yu,et al.  In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses , 2009, Nature Biotechnology.

[12]  Nancy Whiting,et al.  Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  G. Hämmerling,et al.  Targeted Liposomal Delivery of TLR9 Ligands Activates Spontaneous Antitumor Immunity in an Autochthonous Cancer Model1 , 2009, The Journal of Immunology.

[14]  R. Noelle,et al.  Molecular mechanism and function of CD40/CD40L engagement in the immune system , 2009, Immunological reviews.

[15]  M. Smyth,et al.  Locally Administered TLR7 Agonists Drive Systemic Antitumor Immune Responses That Are Enhanced by Anti-CD40 Immunotherapy1 , 2009, The Journal of Immunology.

[16]  R. Houot,et al.  T-cell modulation combined with intratumoral CpG cures lymphoma in a mouse model without the need for chemotherapy. , 2009, Blood.

[17]  N. Van Rooijen,et al.  Macrophages and Fc-receptor interactions contribute to the antitumour activities of the anti-CD40 antibody SGN-40 , 2008, British Journal of Cancer.

[18]  A. Lew,et al.  Deliberately provoking local inflammation drives tumors to become their own protective vaccine site. , 2008, International immunology.

[19]  T. Whiteside.  The tumor microenvironment and its role in promoting tumor growth , 2008, Oncogene.

[20]  S. Fuchs,et al.  Targeting CpG Oligonucleotides to the Lymph Node by Nanoparticles Elicits Efficient Antitumoral Immunity1 , 2008, The Journal of Immunology.

[21]  K. Delman,et al.  Therapy for unresectable recurrent and in-transit extremity melanoma. , 2008, Cancer control : journal of the Moffitt Cancer Center.

[22]  A. Heath,et al.  Liposomal Co-Entrapment of CD40mAb Induces Enhanced IgG Responses against Bacterial Polysaccharide and Protein , 2008, PloS one.

[23]  G. Hämmerling,et al.  Vascular targeting of anti-CD40 antibodies and IL-2 into autochthonous tumors enhances immunotherapy in mice. , 2008, The Journal of clinical investigation.

[24]  S. Gillies,et al.  Intratumoral immunocytokine treatment results in enhanced antitumor effects , 2008, Cancer Immunology, Immunotherapy.

[25]  M. Ernstoff,et al.  Enhanced efficacy and reduced toxicity of multifactorial adjuvants compared with unitary adjuvants as cancer vaccines. , 2008, Blood.

[26]  Jan J. Battermann,et al.  Local therapy of cancer with free IL-2 , 2008, Cancer Immunology, Immunotherapy.

[27]  J. Allison,et al.  Local secretion of anti-CTLA-4 enhances the therapeutic efficacy of a cancer immunotherapy with reduced evidence of systemic autoimmunity , 2008, Cancer Immunology, Immunotherapy.

[28]  Arthur M. Krieg,et al.  Toll-like receptor 9 (TLR9) agonists in the treatment of cancer , 2008, Oncogene.

[29]  A. Rakhmilevich,et al.  CD40 ligation in vivo can induce T cell independent antitumor effects even against immunogenic tumors , 2008, Cancer Immunology, Immunotherapy.

[30]  A. Chang,et al.  Synergistic effect of intratumoral IL-12 and TNF-alpha microspheres: systemic anti-tumor immunity is mediated by both CD8+ CTL and NK cells. , 2007, Surgery.

[31]  M. Smyth,et al.  Immune surveillance of tumors. , 2007, The Journal of clinical investigation.

[32]  U. Galili,et al.  Intratumoral Injection of α-gal Glycolipids Induces Xenograft-Like Destruction and Conversion of Lesions into Endogenous Vaccines , 2007, The Journal of Immunology.

[33]  J. Weiss,et al.  IFN-γ mediates CD4+ T-cell loss and impairs secondary antitumor responses after successful initial immunotherapy , 2007, Nature Medicine.

[34]  J. Christensen,et al.  Agonistic Anti-CD40 Antibody Profoundly Suppresses the Immune Response to Infection with Lymphocytic Choriomeningitis Virus1 , 2007, The Journal of Immunology.

[35]  P. Cullis,et al.  Encapsulation in liposomal nanoparticles enhances the immunostimulatory, adjuvant and anti-tumor activity of subcutaneously administered CpG ODN , 2007, Cancer Immunology, Immunotherapy.

[36]  F. Chisari,et al.  Pathogenic role of B cells in anti-CD40-induced necroinflammatory liver disease. , 2006, The American journal of pathology.

[37]  A. Rakhmilevich,et al.  Synergistic Activation of Macrophages via CD40 and TLR9 Results in T Cell Independent Antitumor Effects1 , 2006, The Journal of Immunology.

[38]  D. Busch,et al.  Systemic application of CpG‐rich DNA suppresses adaptive T cell immunity via induction of IDO , 2006, European journal of immunology.

[39]  K. Flaherty,et al.  Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  B. Baban,et al.  Cutting Edge: CpG Oligonucleotides Induce Splenic CD19+ Dendritic Cells to Acquire Potent Indoleamine 2,3-Dioxygenase-Dependent T Cell Regulatory Functions via IFN Type 1 Signaling1 , 2005, The Journal of Immunology.

[41]  R. J. Kelleher,et al.  Human CD4+ Effector Memory T Cells Persisting in the Microenvironment of Lung Cancer Xenografts Are Activated by Local Delivery of IL-12 to Proliferate, Produce IFN-γ, and Eradicate Tumor Cells1 , 2005, The Journal of Immunology.

[42]  K. Pritchard,et al.  Alpha phenyl-tert-butyl nitrone (PBN) protects syngeneic marrow transplant recipients from the lethal cytokine syndrome occurring after agonistic CD40 antibody administration. , 2004, Blood.

[43]  R. Offringa,et al.  Activation of Dendritic Cells That Cross-Present Tumor-Derived Antigen Licenses CD8+ CTL to Cause Tumor Eradication1 , 2004, The Journal of Immunology.

[44]  J. Frelinger,et al.  Cutting Edge: Tumor-Specific CTL Are Constitutively Cross-Armed in Draining Lymph Nodes and Transiently Disseminate to Mediate Tumor Regression following Systemic CD40 Activation1 , 2004, The Journal of Immunology.

[45]  J. Metzger,et al.  Toll‐like receptor 9 binds single‐stranded CpG‐DNA in a sequence‐ and pH‐dependent manner , 2004, European journal of immunology.

[46]  R. Weichselbaum,et al.  A Phase I Trial of TNFerade Biologic in Patients with Soft Tissue Sarcoma in the Extremities , 2004, Clinical Cancer Research.

[47]  D. Pardoll,et al.  Persistent Toll-like receptor signals are required for reversal of regulatory T cell–mediated CD8 tolerance , 2004, Nature Immunology.

[48]  D. Klinman.  Immunotherapeutic uses of CpG oligodeoxynucleotides , 2004, Nature Reviews Immunology.

[49]  S. Akira,et al.  Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotide administration , 2004, Nature Medicine.

[50]  M. Choti,et al.  Controlled Local Delivery of Interleukin-2 by Biodegradable Polymers Protects Animals from Experimental Brain Tumors and Liver Tumors , 2001, Pharmaceutical Research.

[51]  C. Garbe,et al.  Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases , 2003, British Journal of Cancer.

[52]  B. Boehm,et al.  Intratumor CpG-Oligodeoxynucleotide Injection Induces Protective Antitumor T Cell Immunity 1 , 2003, The Journal of Immunology.

[53]  M. Looman,et al.  Pharmacokinetics and immunological aspects of a phase Ib study with intratumoral administration of recombinant human interleukin-12 in patients with head and neck squamous cell carcinoma: a decrease of T-bet in peripheral blood mononuclear cells. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[54]  A. Nowak,et al.  Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors. , 2003, Cancer research.

[55]  E. Celis,et al.  Immune-mediated tumor regression induced by CpG-containing oligodeoxynucleotides. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[56]  Thomas A. Davis,et al.  Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[57]  J. Wigginton,et al.  Synergistic Anti-Tumor Responses After Administration of Agonistic Antibodies to CD40 and IL-2: Coordination of Dendritic and CD8+ Cell Responses 1 , 2003, The Journal of Immunology.

[58]  M. Sabel,et al.  Cancer immunotherapy with interleukin 12 and granulocyte-macrophage colony-stimulating factor-encapsulated microspheres: coinduction of innate and adaptive antitumor immunity and cure of disseminated disease. , 2002, Cancer research.

[59]  G. Hartmann,et al.  Peritumoral CpG DNA Elicits a Coordinated Response of CD8 T Cells and Innate Effectors to Cure Established Tumors in a Murine Colon Carcinoma Model1 , 2002, The Journal of Immunology.

[60]  G. Trinchieri,et al.  Reversal of Tumor-induced Dendritic Cell Paralysis by CpG Immunostimulatory Oligonucleotide and Anti–Interleukin 10 Receptor Antibody , 2002, The Journal of experimental medicine.

[61]  A. Buzaid,et al.  Phase I trial of subcutaneous recombinant human interleukin‐2 in patients with metastatic melanoma , 2002, Cancer.

[62]  M. Anver,et al.  Administration of either anti-CD40 or interleukin-12 following lethal total body irradiation induces acute lethal toxicity affecting the gut. , 2002, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[63]  R. Offringa,et al.  CD40 stimulation leads to effective therapy of CD40− tumors through induction of strong systemic cytotoxic T lymphocyte immunity , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[64]  M. Glennie,et al.  T Cell Immunity to Lymphoma Following Treatment with Anti-CD40 Monoclonal Antibody1 , 2002, The Journal of Immunology.

[65]  E. Moase,et al.  Use of the post-insertion method for the formation of ligand-coupled liposomes. , 2002, Cellular & molecular biology letters.

[66]  M. C. Popescu,et al.  In situ vaccination against a non-immunogenic tumour using intratumoural injections of liposomal interleukin 2. , 2001, Cytokine.

[67]  M. Grasso,et al.  Neoadiuvant Treatment With Intravesical Interleukin-2 for Recurrent Superficial Transitional Bladder Carcinoma Ta-T1/G1-2 , 2001, Journal of immunotherapy : official journal of the Society for Biological Therapy.

[68]  A. Dalgleish,et al.  CD40 ligation for immunotherapy of solid tumours. , 2001, Journal of immunological methods.

[69]  S. Libutti,et al.  Isolated hepatic perfusion for unresectable hepatic metastases from colorectal cancer. , 2001, Surgery.

[70]  H. Baumann,et al.  Coadministration of interleukin-18 and interleukin-12 induces a fatal inflammatory response in mice: critical role of natural killer cell interferon-gamma production and STAT-mediated signal transduction. , 2000, Blood.

[71]  M. Schuler,et al.  Phase I study of subcutaneously administered recombinant human interleukin 12 in patients with advanced renal cell cancer. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[72]  H. Bien,et al.  Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40 , 1999, Nature Medicine.

[73]  T. Schumacher,et al.  CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy , 1999, Nature Medicine.

[74]  M. Glennie,et al.  CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help , 1999, Nature Medicine.

[75]  R. Geha,et al.  Exogenous CD40 ligand induces a pulmonary inflammation response. , 1997, Journal of immunology.

[76]  D. Pardoll.  Paracrine cytokine adjuvants in cancer immunotherapy. , 1995, Annual review of immunology.

[77]  A. Krieg,et al.  Phosphorothioate oligodeoxynucleotides: antisense or anti-protein? , 1995, Antisense research and development.

[78]  G. Fantuzzi,et al.  Defective inflammatory response in interleukin 6-deficient mice , 1994, The Journal of experimental medicine.

[79]  G. Strassmann,et al.  The role of interleukin-6 in lipopolysaccharide-induced weight loss, hypoglycemia and fibrinogen production, in vivo. , 1993, Cytokine.

[80]  N. Renard,et al.  High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[81]  U. Rüegg,et al.  [10] Reductive cleavage of cystine disulfides with tributylphosphine , 1977 .

[82]  U. Rüegg,et al.  Reductive cleavage of cystine disulfides with tributylphosphine. , 1977, Methods in enzymology.